Chrome 2001
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
. .
Chrome 2001
Chrome 2001
Health News Health News
Glaucoma Drug May Help Reverse Obesity-Related Vision Loss
April 22, 2014


TUESDAY, April 22, 2014 (HealthDay News) -- A drug used to treat glaucoma eye disease can also help people with vision loss linked to obesity, a new study reveals.

Researchers examined the effectiveness of the inexpensive drug, called acetazolamide (Diamox), in women and men with the condition known as "idiopathic intracranial hypertension." According to the researchers, the disorder primarily affects overweight women of reproductive age, and 5 percent to 10 percent of women with it suffer disabling vision loss.

This study included 161 women and four men with idiopathic intracranial hypertension and mild vision loss. The investigators found that adding acetazolamide to a weight-loss plan featuring calorie reduction, lowered salt intake and exercise boosted vision improvement in these patients.

Specifically, the vision of those who took the drug improved twice as much after six months compared to those who took an inactive placebo, according to the U.S. National Eye Institute-funded study published April 22 in the Journal of the American Medical Association.

"Our results show that acetazolamide can help preserve and actually restore vision for women with [idiopathic intracranial hypertension] when combined with a moderate but comprehensive dietary and lifestyle modification plan," Dr. Michael Wall, a professor of neurology and ophthalmology at the University of Iowa in Iowa City, said in a National Eye Institute (NEI) news release.

Doctors need more guidance in treating this condition, another expert noted.

"The vision problems associated with this condition can be extremely debilitating, at significant cost to patients and the health care system. Yet there are no established treatment guidelines. We made it a priority to develop an evidence-based treatment for helping patients keep their vision," Eleanor Schron, director of clinical applications at NEI, said in the news release.

Idiopathic intracranial hypertension occurs when increased pressure within the fluid-filled spaces inside and around the brain causes swelling and damage to the optic nerve, according to the news release. Common symptoms include headache and eye problems such as blind spots, poor side vision, double vision and temporary spells of blindness.

Acetazolamide reduces fluid production in the brain and is often used as an additional treatment -- along with weight loss -- for people with idiopathic intracranial hypertension. However, there has been little evidence that the drug is effective in such cases.

About 100,000 Americans have idiopathic intracranial hypertension, according to the news release, and that number is rising due to the nation's obesity epidemic.

More information

Johns Hopkins Medicine has more about idiopathic intracranial hypertension.
Copyright © 2014 HealthDay. All rights reserved.

SOURCE: U.S. National Eye Institute, news release, April 22, 2014...

More News
InteliHealth .
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
    Print Printer-friendly format    
This website is certified by Health On the Net Foundation. Click to verify.